{
    "organizations": [],
    "uuid": "0441d4aa274e9eb943bc82a45a77080d59708b1e",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/02/13/pr-newswire-bionik-laboratories-reports-third-quarter-fiscal-year-2018-financial-results.html",
    "ord_in_thread": 0,
    "title": "Bionik Laboratories Reports Third Fiscal Year 2018 Financial Results",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "TORONTO and BOSTON, Feb. 13, 2018 /PRNewswire/ -- Bionik Laboratories Corp . (OTCQB: BNKL) (\"Bionik\" or the \"Company\"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced its third quarter fiscal year 2018 financial results for the three and nine months ended December 31, 2017.\nCorporate Highlights\nNamed André Auberton-Hervé, PhD, Chairman of the Board of Directors Dedicated significant commercial and technical resources to the launch of the new generation of InMotion Arm product, including development of significant pipeline of potential customers Signed agreement with Cogmedix to outsource manufacturing, to increase Company's ability to scale faster and meet larger demand following the enhanced version of InMotion launch. Continued development of an InMotion Home product, based on the same clinical concepts and rehabilitation protocols supported by significant clinical data. Entered into a series of agreements to issue convertible notes for a total of $1,901,260 since the end of September 2017 from current and new investors of the Company based in Europe, who have provided total convertible loan funding including interest, fair value of warrants and accretion expense of $5,347,359. New pipe funding of $1,200,000 was closed before December 31, 2017 and $606,400 of additional funding was closed subsequent to December 31, 2017 to date. Entered into a short term loan for $500,000 due March 31, 2018 from one of its directors. Continued development of a lower limb assistive exoskeleton for individual consumers with impaired mobility through previously announced partnership with Wistron Corporation . Progressing through various application processes, as it continues execution of the Chinese joint venture signed earlier this year .\n\"We are confident that the recent launch of our next generation InMotion product will strengthen the commercial pipeline we have built over the last year. Having already placed the first units at major customer hospitals validates the industrial and commercial strategy implemented last year,\" said Dr. Eric Dusseux, Chief Executive Officer and Director of Bionik Laboratories Corp. \"The new agreement with manufacturing partner Cogmedix will increase our production capacity. At the same time, we continue to develop momentum with the key partnerships and joint ventures formed over the summer and have made significant progress as we focus on high growth opportunities within the consumer market.\"\nSummary of Financial Results for the Quarter ended December 31, 2017\nThe Company reported sales of $260,960 for the quarter ended December 31, 2017, as compared to sales of $372,426 for the quarter ended December 31, 2016 and nine month ended sales were $570,327 in 2017 and $553,900 in 2016.\nCost of goods sold was $88,357 and margin was 66% for the quarter ended December 31, 2017 compared to $334,786 and a margin of 10% for the quarter ended December 31, 2016 due to inventory write-offs in 2016.\nFor the quarter ended December 31, 2017, the Company reported a comprehensive loss of $(2,580,759) resulting in a loss per share of $(0.03), compared to a comprehensive loss of $(1,581,759) for the quarter ended December 31, 2016, resulting in loss per share of $(0.02).\nThe Company's cash and cash equivalents at December 31, 2017 was $998,661 compared to $136,080 at September 30, 2017 as a result of the issuance of additional convertible promissory notes. Working capital deficit was ($8,535,488) at December 31, 2017 compared to ($6,492,048) at September 30, 2017.\nBionik Laboratories Corp.\nCondensed Consolidated Interim Balance Sheets\n(Amounts expressed in US Dollars)\nAs at\nDecember 31,\n2017\n(Unaudited)\n$\nAs at\nMarch 31,\n2017\n(As adjusted)\n$\nAssets\nCurrent\nCash and cash equivalents\n998,661\n543,650\nAccounts receivable, net of allowance for doubtful accounts of $16,349 (March 31, 2017 - $10,000)\n306,572\n383,903\nPrepaid expenses and other receivables\n145,044\n228,047\nInventories\n302,414\n228,249\nDue from related parties\n19,374\n18,731\nTotal Current Assets\n1,772,065\n1,402,580\nEquipment\n174,997\n227,421\nTechnology and other assets\n4,783,704\n5,030,624\nGoodwill\n22,308,275\n22,308,275\nTotal Assets\n29,039,041\n28,968,900\nLiabilities and Shareholders' Deficiency\nCurrent\nAccounts Payable\n794,875\n784,771\nAccrued liabilities\n1,868,225\n1,228,657\nCustomer advances\n800\n121,562\nDemand Notes Payable\n50,000\n330,600\nPromissory Notes payable\n-\n236,548\nConvertible Loans Payable\n7,079,852\n2,017,488\nShort term loan\n400,000\n-\nDeferred revenue\n113,801\n98,624\nTotal Current Liabilities\n10,307,553\n4,818,250\nShareholders' Equity\nPreferred Stock, par value $0.001; Authorized 10,000,000 Special Voting Preferred Stock, par\nvalue $0.001; Authorized; Issued and outstanding - 1 (March 31, 2017 – 1)\n-\n-\nCommon Shares, par value $0.001; Authorized - 250,000,000 (March 31, 2017 – 150,000,000);\nIssued and outstanding 53,885,279 and 45,909,336 Exchangeable Shares (March 31, 2017 –\n48,885,107 and 47,909,336 Exchangeable Shares)\n101,794\n96,794\nAdditional paid in capital\n48,081,670\n45,088,171\nShares to be issued\n60,000\n-\nDeficit\n(29,554,125)\n(21,076,464)\nAccumulated other comprehensive income\n42,149\n42,149\nTotal Shareholders' Equity\n18,731,488\n24,150,650\nTotal Liabilities and Shareholders' Equity\n29,039,041\n28,968,900\nBionik Laboratories Corp.\nCondensed Consolidated Interim Statements of Operations and Comprehensive Loss for the three and nine month periods ended December 31, 2017 and 2016 (unaudited)\n(Amounts expressed in U.S. Dollars)\nThree months\nended Dec.\nNine months\nended Dec.\nThree months\nended Dec.\nNine months\nended Dec.\n31, 2017\n31, 2017\n31, 2016\n31, 2016\n$\n(Unaudited)\n$\n(Unaudited)\n$\n(As adjusted)\n$\n(As adjusted)\nSales\n260,960\n570,327\n372,426\n553,900\nCost of Sales\n88,357\n177,482\n334,786\n405,680\nGross Margin\n172,603\n392,845\n37,640\n148,220\nOperating expenses\nSales and marketing\n432,260\n1,313,077\n377,046\n646,509\nResearch and development\n546,350\n1,947,659\n571,671\n1,803,234\nGeneral and administrative\n783,784\n2,916,917\n409,669\n2,291,136\nShare compensation expense\n271,001\n1,284,257\n227,540\n651,630\nConvertible debt accretion\n216,302\n290,375\n-\n-\nAmortization\n76,985\n246,920\n-\n-\nDepreciation\n21,234\n69,606\n24,028\n57,781\nTotal operating expenses\n2,347,916\n8,068,811\n1,609,954\n5,450,290\nOther expenses (income)\nForeign Exchange\n(11,485)\n102,671\n-\n-\nInterest expense\n416,990\n657,350\n13,808\n23,839\nOther income\n(59)\n649\n(4,363)\n(410,877)\nTotal other expenses (income)\n405,446\n760,670\n9,445\n(387,038)\nNet loss and comprehensive loss for the period\n(2,580,759)\n(8,436,636)\n(1,581,759)\n(4,915,032)\nLoss per share – basic\n(0.03)\n$ (0.08)\n(0.02)\n(0.05)\nLoss per share – diluted\n(0.03)\n$ (0.08)\n$ (0.02)\n$ (0.05)\nWeighted average number of shares outstanding – basic\n101,794,615\n99,335,514\n96,362,541\n90,286,864\nWeighted average number of shares outstanding – diluted\n101,794,615\n99,335,514\n96,362,541\n90,286,864\nBionik Laboratories Corp.\nCondensed Consolidated Interim Statements of Cash Flows for the nine months periods\nended December 31, 2017 and 2016 (unaudited)\n(Amounts expressed in U.S. Dollars)\nNine months\nNine months\nended\nended\nDecember 31,\nDecember 31,\n2017\n2016\n$\n$\n(Unaudited)\n(As adjusted)\nOperating activities\nNet loss for the period\n(8,436,636)\n(4,915,032)\nAdjustment for items not affecting cash\nDepreciation\n69,606\n57,781\nAmortization\n246,920\n-\nInterest expense\n640,168\n23,839\nShare based compensation expense\n1,284,257\n592,130\nConvertible debt accretion\n290,375\n-\nShares issued for services\n60,000\n59,500\nAllowance for doubtful accounts\n(16,349)\n-\n(5,861,659)\n(4,181,782)\nChanges in non-cash working capital items\nAccounts receivable\n93,680\n(247,359)\nPrepaid expenses and other receivables\n83,003\n95,562\nDue from related parties\n(643)\n532\nInventories\n(74,165)\n(120,894)\nAccounts payable\n10,104\n(720,573)\nAccrued liabilities\n639,568\n(492,047)\nCustomer advances\n(120,762)\n28,000\nDeferred revenue\n15,177\n97,615\nNet cash used in operating activities\n(5,215,697)\n(5,540,946)\nInvesting activities\nAcquisition of equipment\n(17,182)\n(9,827)\nNet cash used in investing activities\n(17,182)\n(9,827)\nFinancing activities\nProceeds from convertible loans\n4,699,975\n483,333\nProceeds on exercise of warrants\n1,125,038\n-\nRepayment of Promissory note principal\n(200,000)\n-\nRepayment of Promissory note interest\n(49,505)\n-\nRepayment of Demand notes principal\n(208,359)\n-\nRepayment of Demand notes interest\n(79,259)\n-\nProceeds from short term loan\n400,000\n-\nCash acquired on acquisition\n-\n266,635\nNet cash provided by financing activities\n5,687,890\n749,968\nNet decrease in cash and cash equivalents for the period\n455,011\n(4,800,805)\nCash and cash equivalents, beginning of period\n543,650\n5,381,757\nCash and cash equivalents, end of period\n998,661\n580,952\nSupplemental Information:\nAssets acquired and liabilities assumed as at April 21, 2016:\nCurrent assets, including cash of $266,635\n478,843\nEquipment\n59,749\nIntangible assets\n5,580,704\nGoodwill\n22,308,275\nAccounts payable\n(241,299)\nAccrued liabilities\n(361,029)\nCustomer deposits\n(86,487)\nDemand notes payable\n(324,894)\nPromissory Notes payable\n(217,808)\nBionik advance\n(1,436,164)\nNon-cash consideration\n25,759,890\nThe above financial information has been derived from the Company's unaudited consolidated condensed financial statements as of December 31, 2017 and 2016, and should be read in conjunction with the consolidated financial statements, including the notes thereto, found in the Company's Quarterly Report on Form 10-Q filed with the SEC on February 13, 2018 and Annual Report on Form 10-K for the year ended March 31, 2017 filed with the SEC on June 29, 2017.\nThe Company will require additional financing this year to fund its operations and it is currently working on securing this funding through corporate collaborations, public or private equity offerings and/or debt financings, and is subject to a going concern qualification.\nAbout Bionik Laboratories Corp.\nBionik Laboratories (OTCQB:BNKL) is a robotics company focused on providing rehabilitation and mobility solutions to individuals with neurological and mobility challenges from hospital to home. The Company has a portfolio of products focused on upper and lower extremity rehabilitation for stroke and other mobility-impaired patients, including three products on the market and four products in varying stages of development.\nFor more information, please visit www.bioniklabs.com and connect with us on Twitter , LinkedIn , and Facebook .\nForward-Looking Statements\nAny statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words \"may,\" \"should,\" \"would,\" \"will,\" \"could,\" \"scheduled,\" \"expect,\" \"anticipate,\" \"estimate,\" \"believe,\" \"intend,\" \"seek,\" or \"project\" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons and other robotic rehabilitation products, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, pipeline of potential sales, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the market and projected market for our existing and planned products and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances, and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions, and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of our products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company's raw materials, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company does not undertake to update these forward-looking statements.\nView original content with multimedia: http://www.prnewswire.com/news-releases/bionik-laboratories-reports-third-quarter-fiscal-year-2018-financial-results-300598255.html\nSOURCE Bionik Laboratories Corp.",
    "published": "2018-02-14T00:02:00.000+02:00",
    "crawled": "2018-02-14T02:02:27.012+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "toronto",
        "boston",
        "bionik",
        "laboratory",
        "corp",
        "otcqb",
        "bnkl",
        "bionik",
        "company",
        "robotics",
        "company",
        "focused",
        "providing",
        "rehabilitation",
        "assistive",
        "technology",
        "solution",
        "individual",
        "neurological",
        "mobility",
        "challenge",
        "hospital",
        "home",
        "today",
        "announced",
        "third",
        "quarter",
        "fiscal",
        "year",
        "financial",
        "result",
        "three",
        "nine",
        "month",
        "ended",
        "december",
        "corporate",
        "highlight",
        "named",
        "andré",
        "phd",
        "chairman",
        "board",
        "director",
        "dedicated",
        "significant",
        "commercial",
        "technical",
        "resource",
        "launch",
        "new",
        "generation",
        "inmotion",
        "arm",
        "product",
        "including",
        "development",
        "significant",
        "pipeline",
        "potential",
        "customer",
        "signed",
        "agreement",
        "cogmedix",
        "outsource",
        "manufacturing",
        "increase",
        "company",
        "ability",
        "scale",
        "faster",
        "meet",
        "larger",
        "demand",
        "following",
        "enhanced",
        "version",
        "inmotion",
        "launch",
        "continued",
        "development",
        "inmotion",
        "home",
        "product",
        "based",
        "clinical",
        "concept",
        "rehabilitation",
        "protocol",
        "supported",
        "significant",
        "clinical",
        "data",
        "entered",
        "series",
        "agreement",
        "issue",
        "convertible",
        "note",
        "total",
        "since",
        "end",
        "september",
        "current",
        "new",
        "investor",
        "company",
        "based",
        "europe",
        "provided",
        "total",
        "convertible",
        "loan",
        "funding",
        "including",
        "interest",
        "fair",
        "value",
        "warrant",
        "accretion",
        "expense",
        "new",
        "pipe",
        "funding",
        "closed",
        "december",
        "additional",
        "funding",
        "closed",
        "subsequent",
        "december",
        "date",
        "entered",
        "short",
        "term",
        "loan",
        "due",
        "march",
        "one",
        "director",
        "continued",
        "development",
        "lower",
        "limb",
        "assistive",
        "exoskeleton",
        "individual",
        "consumer",
        "impaired",
        "mobility",
        "previously",
        "announced",
        "partnership",
        "wistron",
        "corporation",
        "progressing",
        "various",
        "application",
        "process",
        "continues",
        "execution",
        "chinese",
        "joint",
        "venture",
        "signed",
        "earlier",
        "year",
        "confident",
        "recent",
        "launch",
        "next",
        "generation",
        "inmotion",
        "product",
        "strengthen",
        "commercial",
        "pipeline",
        "built",
        "last",
        "year",
        "already",
        "placed",
        "first",
        "unit",
        "major",
        "customer",
        "hospital",
        "validates",
        "industrial",
        "commercial",
        "strategy",
        "implemented",
        "last",
        "year",
        "said",
        "eric",
        "dusseux",
        "chief",
        "executive",
        "officer",
        "director",
        "bionik",
        "laboratory",
        "new",
        "agreement",
        "manufacturing",
        "partner",
        "cogmedix",
        "increase",
        "production",
        "capacity",
        "time",
        "continue",
        "develop",
        "momentum",
        "key",
        "partnership",
        "joint",
        "venture",
        "formed",
        "summer",
        "made",
        "significant",
        "progress",
        "focus",
        "high",
        "growth",
        "opportunity",
        "within",
        "consumer",
        "market",
        "summary",
        "financial",
        "result",
        "quarter",
        "ended",
        "december",
        "company",
        "reported",
        "sale",
        "quarter",
        "ended",
        "december",
        "compared",
        "sale",
        "quarter",
        "ended",
        "december",
        "nine",
        "month",
        "ended",
        "sale",
        "cost",
        "good",
        "sold",
        "margin",
        "quarter",
        "ended",
        "december",
        "compared",
        "margin",
        "quarter",
        "ended",
        "december",
        "due",
        "inventory",
        "quarter",
        "ended",
        "december",
        "company",
        "reported",
        "comprehensive",
        "loss",
        "resulting",
        "loss",
        "per",
        "share",
        "compared",
        "comprehensive",
        "loss",
        "quarter",
        "ended",
        "december",
        "resulting",
        "loss",
        "per",
        "share",
        "company",
        "cash",
        "cash",
        "equivalent",
        "december",
        "compared",
        "september",
        "result",
        "issuance",
        "additional",
        "convertible",
        "promissory",
        "note",
        "working",
        "capital",
        "deficit",
        "december",
        "compared",
        "september",
        "bionik",
        "laboratory",
        "condensed",
        "consolidated",
        "interim",
        "balance",
        "sheet",
        "amount",
        "expressed",
        "u",
        "dollar",
        "december",
        "unaudited",
        "march",
        "adjusted",
        "asset",
        "current",
        "cash",
        "cash",
        "equivalent",
        "account",
        "receivable",
        "net",
        "allowance",
        "doubtful",
        "account",
        "march",
        "prepaid",
        "expense",
        "receivables",
        "inventory",
        "due",
        "related",
        "party",
        "total",
        "current",
        "asset",
        "equipment",
        "technology",
        "asset",
        "goodwill",
        "total",
        "asset",
        "liability",
        "shareholder",
        "deficiency",
        "current",
        "account",
        "payable",
        "accrued",
        "liability",
        "customer",
        "advance",
        "demand",
        "note",
        "payable",
        "promissory",
        "note",
        "payable",
        "convertible",
        "loan",
        "payable",
        "short",
        "term",
        "loan",
        "deferred",
        "revenue",
        "total",
        "current",
        "liability",
        "shareholder",
        "equity",
        "preferred",
        "stock",
        "par",
        "value",
        "authorized",
        "special",
        "voting",
        "preferred",
        "stock",
        "par",
        "value",
        "authorized",
        "issued",
        "outstanding",
        "march",
        "common",
        "share",
        "par",
        "value",
        "authorized",
        "march",
        "issued",
        "outstanding",
        "exchangeable",
        "share",
        "march",
        "exchangeable",
        "share",
        "additional",
        "paid",
        "capital",
        "share",
        "issued",
        "deficit",
        "accumulated",
        "comprehensive",
        "income",
        "total",
        "shareholder",
        "equity",
        "total",
        "liability",
        "shareholder",
        "equity",
        "bionik",
        "laboratory",
        "condensed",
        "consolidated",
        "interim",
        "statement",
        "operation",
        "comprehensive",
        "loss",
        "three",
        "nine",
        "month",
        "period",
        "ended",
        "december",
        "unaudited",
        "amount",
        "expressed",
        "dollar",
        "three",
        "month",
        "ended",
        "nine",
        "month",
        "ended",
        "three",
        "month",
        "ended",
        "nine",
        "month",
        "ended",
        "unaudited",
        "unaudited",
        "adjusted",
        "adjusted",
        "sale",
        "cost",
        "sale",
        "gross",
        "margin",
        "operating",
        "expense",
        "sale",
        "marketing",
        "research",
        "development",
        "general",
        "administrative",
        "share",
        "compensation",
        "expense",
        "convertible",
        "debt",
        "accretion",
        "amortization",
        "depreciation",
        "total",
        "operating",
        "expense",
        "expense",
        "income",
        "foreign",
        "exchange",
        "interest",
        "expense",
        "income",
        "total",
        "expense",
        "income",
        "net",
        "loss",
        "comprehensive",
        "loss",
        "period",
        "loss",
        "per",
        "share",
        "basic",
        "loss",
        "per",
        "share",
        "diluted",
        "weighted",
        "average",
        "number",
        "share",
        "outstanding",
        "basic",
        "weighted",
        "average",
        "number",
        "share",
        "outstanding",
        "diluted",
        "bionik",
        "laboratory",
        "condensed",
        "consolidated",
        "interim",
        "statement",
        "cash",
        "flow",
        "nine",
        "month",
        "period",
        "ended",
        "december",
        "unaudited",
        "amount",
        "expressed",
        "dollar",
        "nine",
        "month",
        "nine",
        "month",
        "ended",
        "ended",
        "december",
        "december",
        "unaudited",
        "adjusted",
        "operating",
        "activity",
        "net",
        "loss",
        "period",
        "adjustment",
        "item",
        "affecting",
        "cash",
        "depreciation",
        "amortization",
        "interest",
        "expense",
        "share",
        "based",
        "compensation",
        "expense",
        "convertible",
        "debt",
        "accretion",
        "share",
        "issued",
        "service",
        "allowance",
        "doubtful",
        "account",
        "change",
        "working",
        "capital",
        "item",
        "account",
        "receivable",
        "prepaid",
        "expense",
        "receivables",
        "due",
        "related",
        "party",
        "inventory",
        "account",
        "payable",
        "accrued",
        "liability",
        "customer",
        "advance",
        "deferred",
        "revenue",
        "net",
        "cash",
        "used",
        "operating",
        "activity",
        "investing",
        "activity",
        "acquisition",
        "equipment",
        "net",
        "cash",
        "used",
        "investing",
        "activity",
        "financing",
        "activity",
        "proceeds",
        "convertible",
        "loan",
        "proceeds",
        "exercise",
        "warrant",
        "repayment",
        "promissory",
        "note",
        "principal",
        "repayment",
        "promissory",
        "note",
        "interest",
        "repayment",
        "demand",
        "note",
        "principal",
        "repayment",
        "demand",
        "note",
        "interest",
        "proceeds",
        "short",
        "term",
        "loan",
        "cash",
        "acquired",
        "acquisition",
        "net",
        "cash",
        "provided",
        "financing",
        "activity",
        "net",
        "decrease",
        "cash",
        "cash",
        "equivalent",
        "period",
        "cash",
        "cash",
        "equivalent",
        "beginning",
        "period",
        "cash",
        "cash",
        "equivalent",
        "end",
        "period",
        "supplemental",
        "information",
        "asset",
        "acquired",
        "liability",
        "assumed",
        "april",
        "current",
        "asset",
        "including",
        "cash",
        "equipment",
        "intangible",
        "asset",
        "goodwill",
        "account",
        "payable",
        "accrued",
        "liability",
        "customer",
        "deposit",
        "demand",
        "note",
        "payable",
        "promissory",
        "note",
        "payable",
        "bionik",
        "advance",
        "consideration",
        "financial",
        "information",
        "derived",
        "company",
        "unaudited",
        "consolidated",
        "condensed",
        "financial",
        "statement",
        "december",
        "read",
        "conjunction",
        "consolidated",
        "financial",
        "statement",
        "including",
        "note",
        "thereto",
        "found",
        "company",
        "quarterly",
        "report",
        "form",
        "filed",
        "sec",
        "february",
        "annual",
        "report",
        "form",
        "year",
        "ended",
        "march",
        "filed",
        "sec",
        "june",
        "company",
        "require",
        "additional",
        "financing",
        "year",
        "fund",
        "operation",
        "currently",
        "working",
        "securing",
        "funding",
        "corporate",
        "collaboration",
        "public",
        "private",
        "equity",
        "offering",
        "debt",
        "financing",
        "subject",
        "going",
        "concern",
        "qualification",
        "bionik",
        "laboratory",
        "bionik",
        "laboratory",
        "otcqb",
        "bnkl",
        "robotics",
        "company",
        "focused",
        "providing",
        "rehabilitation",
        "mobility",
        "solution",
        "individual",
        "neurological",
        "mobility",
        "challenge",
        "hospital",
        "home",
        "company",
        "portfolio",
        "product",
        "focused",
        "upper",
        "lower",
        "extremity",
        "rehabilitation",
        "stroke",
        "patient",
        "including",
        "three",
        "product",
        "market",
        "four",
        "product",
        "varying",
        "stage",
        "development",
        "information",
        "please",
        "visit",
        "connect",
        "u",
        "twitter",
        "linkedin",
        "facebook",
        "statement",
        "statement",
        "contained",
        "press",
        "release",
        "describe",
        "historical",
        "fact",
        "may",
        "constitute",
        "statement",
        "statement",
        "involve",
        "assumption",
        "describe",
        "future",
        "plan",
        "strategy",
        "expectation",
        "generally",
        "identifiable",
        "use",
        "word",
        "may",
        "would",
        "could",
        "scheduled",
        "expect",
        "anticipate",
        "estimate",
        "believe",
        "intend",
        "seek",
        "project",
        "negative",
        "word",
        "variation",
        "word",
        "comparable",
        "terminology",
        "statement",
        "may",
        "include",
        "without",
        "limitation",
        "statement",
        "regarding",
        "plan",
        "objective",
        "management",
        "future",
        "operation",
        "including",
        "plan",
        "objective",
        "relating",
        "design",
        "development",
        "commercialization",
        "human",
        "exoskeleton",
        "robotic",
        "rehabilitation",
        "product",
        "ii",
        "projection",
        "income",
        "including",
        "earnings",
        "including",
        "per",
        "share",
        "capital",
        "expenditure",
        "dividend",
        "pipeline",
        "potential",
        "sale",
        "capital",
        "structure",
        "financial",
        "item",
        "iii",
        "company",
        "future",
        "financial",
        "performance",
        "iv",
        "market",
        "projected",
        "market",
        "existing",
        "planned",
        "product",
        "v",
        "assumption",
        "underlying",
        "relating",
        "statement",
        "described",
        "point",
        "ii",
        "iii",
        "iv",
        "statement",
        "meant",
        "predict",
        "guarantee",
        "actual",
        "result",
        "performance",
        "event",
        "circumstance",
        "may",
        "realized",
        "based",
        "upon",
        "company",
        "current",
        "projection",
        "plan",
        "objective",
        "belief",
        "expectation",
        "estimate",
        "assumption",
        "subject",
        "number",
        "risk",
        "uncertainty",
        "influence",
        "many",
        "company",
        "control",
        "actual",
        "result",
        "timing",
        "certain",
        "event",
        "circumstance",
        "may",
        "differ",
        "materially",
        "described",
        "statement",
        "result",
        "risk",
        "uncertainty",
        "factor",
        "may",
        "influence",
        "contribute",
        "inaccuracy",
        "statement",
        "cause",
        "actual",
        "result",
        "differ",
        "materially",
        "expected",
        "desired",
        "result",
        "may",
        "include",
        "without",
        "limitation",
        "company",
        "inability",
        "obtain",
        "additional",
        "financing",
        "significant",
        "length",
        "time",
        "resource",
        "associated",
        "development",
        "product",
        "related",
        "insufficient",
        "cash",
        "flow",
        "resulting",
        "illiquidity",
        "company",
        "inability",
        "expand",
        "company",
        "business",
        "significant",
        "government",
        "regulation",
        "medical",
        "device",
        "healthcare",
        "industry",
        "lack",
        "product",
        "diversification",
        "volatility",
        "price",
        "company",
        "raw",
        "material",
        "company",
        "failure",
        "implement",
        "company",
        "business",
        "plan",
        "strategy",
        "factor",
        "identified",
        "described",
        "detail",
        "company",
        "filing",
        "sec",
        "company",
        "undertake",
        "update",
        "statement",
        "view",
        "original",
        "content",
        "multimedia",
        "http",
        "source",
        "bionik",
        "laboratory",
        "corp"
    ]
}